+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Overexpression of mdm2 and p53 and association with progesterone receptor expression in benign meningiomas



Overexpression of mdm2 and p53 and association with progesterone receptor expression in benign meningiomas



Neuropathology 22(3): 194-199



The progesterone receptor is frequently found expressed in meningiomas at robust levels. As several studies of breast and endometrial tumors have shown an inverse correlation between progesterone receptor expression and p53 overexpression, we sought to determine if a similar relationship existed in meningiomas. As p53 may also be inactivated by the overexpression of mdm2, we examined a cohort of 90 benign meningiomas immunohistochemically for the presence of the progesterone receptor as well as overexpression of p53 and mdm2. The progesterone receptor was detected in 67% (61/90) of cases, while p53 and mdm2 overexpression were detected in 14% (13/90) and 46% (42/90) of cases, respectively. An absolute correlation was observed between the overexpression of nuclear mdm2 and overexpression of the progesterone receptor, with nuclear mdm2 overexpression being confined to progesterone receptor-positive tumors (P = 0.001). While p53 overexpression was not associated with progesterone receptor expression, a combination of mdm2 overexpression and/or p53 overexpression was significantly associated with the presence of the progesterone receptor (P = 0.025). These results suggest the existence of a novel relationship between p53 (and its regulatory control) and the presence of the progesterone receptor and, as such, may have fundamental consequences in developing progesterone receptor-targeted therapies for meningiomas.

(PDF emailed within 0-6 h: $19.90)

Accession: 046897045

Download citation: RISBibTeXText

PMID: 12416559

DOI: 10.1046/j.1440-1789.2002.00443.x


Related references

The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas. In Vivo 16(4): 265-270, 2002

Progesterone receptors expression in benign meningiomas. Virchows Archiv 443(3): 367, 2003

Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Cancer 104(3): 598-601, 2005

Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clinical Cancer Research 6(9): 3570-3575, 2000

Progesterone receptor expression in meningiomas. Cancer Research 53(6): 1312-1316, 1993

Progesterone receptor, bc1-2 and bax expression in meningiomas. Journal of Neuro-Oncology 56(1): 35-41, 2002

The truncated estrogen receptor alpha variant lacking exon 5 is not involved in progesterone receptor expression in meningiomas. Journal of Steroid Biochemistry and Molecular Biology 71(5-6): 167-172, 2000

The truncated estrogen receptor alpha variant lacking exon 5 is not involved in progesterone receptor expression in meningiomas. Journal of Steroid Biochemistry & Molecular Biology 71(5-6): 167-172, Dec 31, 1999

Progesterone receptor isoform expression in human meningiomas. European Journal of Cancer 37(12): 1488-1495, 2001

Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Research & Treatment 71(1): 77-84, 2002

Her-2/neu, estrogen and progesterone receptor expression in WHO grade I meningiomas: A pilot study. 2007

Expression of the C-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas. Acta Neuropathologica. 86(5): 473-479, 1993

Evaluation of progesterone and estrogen receptor expression in 15 meningiomas of dogs and cats. American Journal of Veterinary Research 64(10): 1310-1318, 2003

Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas. Journal of Endocrinology 148(SUPPL ): OC5, 1996

Expression profile of p53, p73, MDM2 and p21WAF1/C1P1 in benign prostate hyperplasia and prostate cancer Alternative splicing deregulation leads to overexpression of exon 13 p73 isoforms. International Journal of Molecular Medicine 8(Supplement 1): S96, 2001